Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 43-54

  Keane, Fiona M ^a,b   Yao, Tsun Wen ^a,b,h   Seelk, Stefanie ^a   Gall, Margaret G ^a,b   Chowdhury, Sumaiya ^a,b   Poplawski, Sarah E ^c   Lai, Jack H ^c   Li, Youhua ^c   Wu, Wengen ^c   Farrell, Penny ^d   Vieira de Ribeiro, Ana Julia ^a,b   Osborne, Brenna ^a,b,i   Yu, Denise M T ^a,b,j   Seth, Devanshi ^a,d   Rahman, Khairunnessa ^d   Haber, Paul ^b,d   Topaloglu, A Kemal ^e   Wang, Chuanmin ^b,d   Thomson, Sally ^b,d   Hennessy, Annemarie ^d,f   Prins, John ^g   Twigg, Stephen M ^b,d   McLennan, Susan V ^b,d   McCaughan, Geoffrey W ^a,b   Bachovchin, William W ^c   Gorrell, Mark D ^a,b   more..

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e CUKUROVA UNIVERSITY   (Turkey)

^f UNIVERSITY OF WESTERN SYDNEY   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

Biomarker; Dipeptidyl peptidase; Fibroblast; Fibrosis; Liver disease; Protease activity; Protease substrates

Indexed keywords

FIBROBLAST ACTIVATION PROTEIN; PROTEINASE; UNCLASSIFIED DRUG; PROTEIN;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ARTICLE; BABOON; CHRONIC LIVER DISEASE; COLON; ENZYME ACTIVITY; EPIDIDYMIS; HUMAN; LEUKOCYTE; LIVER DISEASE; LIVER FIBROSIS; LIVER HOMOGENATE; LYMPH NODE; MESENCHYME CELL; NONHUMAN; PANCREAS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROSTATE; SKIN; SUBMANDIBULAR GLAND; TESTIS; UTERUS; ADOLESCENT; ADULT; AGED; BLADDER; BRAIN; CONTROLLED STUDY; DERMATOMYCOSIS; ENZYME ASSAY; FEMALE; FIBROBLAST; GENE INACTIVATION; HUMAN TISSUE; KNOCKOUT MOUSE; LIQUID; LIVER; MALE; MOUSE; NERVE; ORGAN; TONGUE;

MUS; PAPIO;

EID: 84890386346     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2013.12.001     Document Type: Article

References (73)

1. Turk B., Turk D., Turk V. Protease signalling: the cutting edge. EMBO J. 2012, 31:1630-1643.
2. Gorrell MD., Park J.E. Fibroblast activation protein alpha. Handbook of Proteolytic Enzymes 2013, 3395-3401. Elsevier, San Diego. third ed.
3. Keane F.M., Chowdhury S., Yao T.-W., Nadvi N.A., Gall M.G., Chen Y., Osborne B., Vieira de Ribeiro A.J., Church W.B., McCaughan G.W., et al. Targeting dipeptidyl peptidase-4 (DPP-4) and fibroblast activation protein (FAP) for diabetes and cancer therapy. Proteinases as Drug Targets 2012, 119-145. Royal Society of Chemistry, Cambridge, UK. B. Dunn (Ed.).
4. Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. (Lond) 2005, 108:277-292.
5. Kim Y.O., Schuppan D. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G759-G761.
6. Keane F.M., Nadvi N.A., Yao T.-W., Gorrell M.D. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS. J. 2011, 278:1316-1332.
7. Levy M.T., McCaughan G.W., Abbott C.A., Park J.E., Cunningham A.M., Muller E., Rettig W.J., Gorrell M.D. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999, 29:1768-1778.
8. Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., Rettig W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999, 274:36505-36512.
9. Lee K.N., Jackson K.W., Christiansen V.J., Chung K.H., McKee P.A. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Bloodd 2004, 103:3783-3788.
10. Lee K.N., Jackson K.W., Christiansen V.J., Lee C.S., Chun J.G., McKee P.A. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006, 107:1397-1404.
11. Niedermeyer J., Garin-Chesa P., Kriz M., Hilberg F., Mueller E., Bamberger U., Rettig W.J., Schnapp A. Expression of the fibroblast activation protein during mouse embryo development. Int. J. Dev. Biol. 2001, 45:445-447.
12. Hua X., Yu L., Huang X., Liao Z., Xian Q. Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn. Pathol. 2011, 6:111.
13. Mentlein R., Hattermann K., Hemion C., Jungbluth A.A., Held-Feindt J. Expression and role of the cell surface protease seprase/fibroblast activation protein-alpha (FAP-alpha) in astroglial tumors. Biol. Chem. 2011, 392:199-207.
14. Shi M., Yu D.H., Chen Y., Zhao C.Y., Zhang J., Liu Q.H., Ni C.R., Zhu M.H. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 2012, 18:840-846.
15. Wang X.M., Yu D.M., McCaughan G.W., Gorrell M.D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005, 42:935-945.
16. Bauer S., Jendro M.C., Wadle A., Kleber S., Stenner F., Dinser R., Reich A., Faccin E., Godde S., Dinges H., et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res. Ther. 2006, 8:R171.
17. Brokopp C.E., Schoenauer R., Richards P., Bauer S., Lohmann C., Emmert M.Y., Weber B., Winnik S., Aikawa E., Graves K., et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur. Heart J. 2011, 32:2713-2722.
18. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:7235-7239.
19. Brennen W.N., Isaacs J.T., Denmeade S.R. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther. 2012, 11:257-266.
20. Liu R., Li H., Liu L., Yu J., Ren X. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol. Ther. 2012, 13:123-129.
21. Wen Y., Wang C., Ma T., Li Z., Zhou L., Mu B., Leng F., Shi H., Li Y., Wei Y. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010, 101:2325-2332.
22. Gorrell M.D., Gysbers V., McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 2001, 54:249-264.
23. Harstad E.B., Rosenblum J.S., Gorrell M.D., Achanzar W.E., Minimo L., Wu J., Rosini-Marthaler L., Gullo R., Ordway N.D., Kirby M.S., et al. DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues. Regul. Pept. 2013, 186:26-35.
24. McCaughan G.W., Wickson J.E., Creswick P.F., Gorrell M.D. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology 1990, 11:534-544.
25. Yu D.M., Ajami K., Gall M.G., Park J., Lee C.S., Evans K.A., McLaughlin E.A., Pitman M.R., Abbott C.A., McCaughan G.W., et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J. Histochem. Cytochem. 2009, 57:1025-1040.
26. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214:829-835.
27. Heymann E., Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 1978, 91:360-364.
28. Mentlein R., Dahms P., Grandt D., Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 1993, 49:133-144.
29. Oravecz T., Pall M., Roderiquez G., Gorrell M.D., Ditto M., Nguyen N.Y., Boykins R., Unsworth E., Norcross M.A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 1997, 186:1865-1872.
30. Proost P., Menten P., Struyf S., Schutyser E., De Meester I., Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000, 96:1674-1680.
31. Cordero O.J., Salgado F.J., Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 2009, 58:1723-1747.
32. Yildirim F.E., Karaduman A., Pinar A., Aksoy Y. CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy. Int. J. Dermatol. 2011, 50:948-955.
33. Fletcher M.A., Zeng X.R., Maher K., Levis S., Hurwitz B., Antoni M., Broderick G., Klimas N.G. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010, 5:e10817.
34. Kupeli E., Karnak D., Elgun S., Arguder E., Kayacan O. Concurrent measurement of adenosine deaminase and dipeptidyl peptidase IV activity in the diagnosis of tuberculous pleural effusion. Diagn. Microbiol. Infect. Dis. 2009, 65:365-371.
35. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., Mallet V., Mottez E., Mapes J., Fontanet A., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV (hepatitis C virus). J. Clin. Invest. 2011, 121:308-318.
36. Itou M., Kawaguchi T., Taniguchi E., Hirano E., Sumie S., Oriishi T., Mitsuyama K., Tsuruta O., Ueno T., Sata M. Altered expression of glucagon-like peptide and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J. Gastroenterol. Hepatol. 2008, 23:244-251.
37. Amatya V.J., Takeshima Y., Kushitani K., Yamada T., Morimoto C., Inai K. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncol. Rep. 2011, 26:1369-1375.
38. Arwert E.N., Mentink R.A., Driskell R.R., Hoste E., Goldie S.J., Quist S., Watt F.M. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene 2012, 31:992-1000.
39. Ayude D., Paez de la Cadena M., Cordero O.J., Nogueira M., Ayude J., Fernandez-Briera A., Rodriguez-Berrocal F.J. Clinical interest of the combined use of serum CD26 and alpha-L-fucosidase in the early diagnosis of colorectal cancer. Dis. Markers 2003, 19:267-272.
40. Javidroozi M., Zucker S., Chen W.T. Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis. Markers 2012, 32:309-320.
41. Khin E.E., Kikkawa F., Ino K., Kajiyama H., Suzuki T., Shibata K., Tamakoshi K., Nagasaka T., Mizutani S. Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am. J. Obstet. Gynecol. 2003, 188:670-676.
42. Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I., Cremasco F., Ognibene A., Rotella C.M. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005, 48:1168-1172.
43. Ryskjaer J., Deacon C.F., Carr R.D., Krarup T., Madsbad S., Holst J., Vilsboll T. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 2006, 155:485-493.
44. McKillop A.M., Duffy N.A., Lindsay J.R., O'Harte F.P., Bell P.M., Flatt P.R. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res. Clin. Pract. 2008, 79:79-85.
45. Meneilly G.S., Demuth H.U., McIntosh C.H., Pederson R.A. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet. Med. 2000, 17:346-350.
46. Jambunathan K., Watson D.S., Endsley A.N., Kodukula K., Galande A.K. Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein alpha. FEBS Lett. 2012, 586:2507-2512.
47. Niedermeyer J., Scanlan M.J., Garin-Chesa P., Daiber C., Fiebig H.H., Old L.J., Rettig W.J., Schnapp A. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int. J. Cancer. 1997, 71:383-389.
48. Yuan D., Liu B., Liu K., Zhu G., Dai Z., Xie Y. Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma. J. Surg. Oncol. 2013, 108:157-162.
49. Jacob M., Chang L., Pure E. Fibroblast activation protein in remodeling tissues. Curr. Mol. Med. 2012, 12:1220-1243.
50. Christiansen V.J., Jackson K.W., Lee K.N., Downs T.D., McKee P.A. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia 2013, 15:348-358.
51. Fischer E., Chaitanya K., Wuest T., Wadle A., Scott A.M., van den Broek M., Schibli R., Bauer S., Renner C. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin. Cancer Res. 2012, 18:6208-6218.
52. LeBeau A.M., Brennen W.N., Aggarwal S., Denmeade S.R. Targeting cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol. Cancer Ther. 2009, 8:1378-1386.
53. Kakarla S., Chow K.K., Mata M., Shaffer D.R., Song X.T., Wu M.F., Liu H., Wang L.L., Rowley D.R., Pfizenmaier K., et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther. 2013, 21:1611-1620.
54. Cai F., Li Z., Wang C., Xian S., Xu G., Peng F., Wei Y., Lu Y. Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model. BMB Rep. 2013, 46:252-257.
55. Roberts E.W., Deonarine A., Jones J.O., Denton A.E., Feig C., Lyons S.K., Espeli M., Kraman M., McKenna B., Wells R.J., et al. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 2013, 210:1137-1151.
56. Tran E., Chinnasamy D., Yu Z., Morgan R.A., Lee C.C., Restifo N.P., Rosenberg S.A. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 2013, 210:1125-1135.
57. Poplawski S.E., Li Y., Shu Y., Zhang M., DiMare M.T., Sanford D.G., Lai J.H., Cheng J.D., Alpaugh K.R., Gorrell M.D., et al. Cancerous tissues from human patients contain far higher levels of fibroblast activation protein enzyme activity than corresponding mouse xenografts as revealed using ARI-3144, a new highly specific substrate assay. Cancer Cell 2013, Submitted.
58. Niedermeyer J., Kriz M., Hilberg F., Garin-Chesa P., Bamberger U., Lenter M.C., Park J., Viertel B., Puschner H., Mauz M., et al. Targeted disruption of mouse fibroblast activation protein. Mol. Cell Biol. 2000, 20:1089-1094.
59. Osborne B., Yao T.-W., Wang X.M., Kotan L.D., Nadvi N.A., Herdem M., Yu D.M.T., Allen J.D., Topaloglu A.K., Gorrell M.D. A rare variant in human fibroblast activation protein associated with ER stress, loss of function and loss of cell surface localisation. Biochim. Biophys. Acta Proteins Proteomics 2013, Submitted.
60. Chowdhury S., Chen Y., Yao T.-W., Ajami K., Wang X.M., Popov Y., Schuppan D., Bertolino P., McCaughan G.W., Yu D.M., et al. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. World J. Gastroenterol. 2013, 19:2883-2893.
61. Wang X.M., Yao T.W., Nadvi N.A., Osborne B., McCaughan G.W., Gorrell M.D. Fibroblast activation protein and chronic liver disease. Front. Biosci. 2008, 13:3168-3180.
62. Li J., Chen K., Liu H., Cheng K., Yang M., Zhang J., Cheng JD., Zhang Y., Cheng Z. Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha. Bioconjug. Chem. 2012, 23:1704-1711.
63. Santos A.M., Jung J., Aziz N., Kissil J.L., Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 2010, 119:3613-3626.
64. Abbott C.A., Gorrell M.D., Kobayashi Y., Kawasaki T., Liddle C., Bishop G.A., McCaughan G.W. Increased serum levels of dipeptidyl peptidase IV (CD26) in rats undergoing liver regeneration. Int. Hepatol. Commun. 1995, 4:165-174.
65. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M., Eckardt K., Kaufman J.M., Ryden M., Müller S., et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011, 60:1917-1925.
66. Gorrell M.D. Editorial: impaired glucose tolerance and incretins in chronic liver disease. J. Gastroenterol. Hepatol. 2008, 23:166-167.
67. Lee S., Macquillan G.C., Keane N.M., Flexman J., Jeffrey G.P., French M.A., Brochier J., Price P. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol. Cell. Biol. 2002, 80:391-397.
68. Matsumoto Y., Bishop G.A., McCaughan G.W. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology 1992, 15:1048-1053.
69. Lee K.N., Jackson K.W., Christiansen V.J, Dolence E.K., McKee P.A. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor alpha2-antiplasmin. J. Thromb. Haemost. 2011, 9:987-996.
70. Wild N., Andres H., Rollinger W., Krause F., Dilba P., Tacke M., Karl J. A combination of serum markers for the early detection of colorectal cancer. Clin. Cancer Res. 2010, 16:6111-6121.
71. Levy M.T., McCaughan G.W., Marinos G., Gorrell M.D. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 2002, 22:93-101.
72. Thomson S.E., McLennan S.V., Hennessy A., Boughton P., Bonner J., Zoellner H., Yue D.K., Twigg S.M. A novel primate model of delayed wound healing in diabetes: dysregulation of connective tissue growth factor. Diabetologia 2010, 53:572-583.
73. Song S., Shackel N.A., Wang X.M., Ajami K., McCaughan G.W., Gorrell M.D. Discoidin domain receptor 1: isoform expression and potential functions in cirrhotic human liver. Am. J. Pathol. 2011, 178:1134-1144.